Institute of Science Tokyo · Graduate School of Medical and Dental Sciences · 准教授

Research keywordsulcerative colitis・Crohn disease・anti-integrin alphaVbeta6・serum biomarker・first-line biologics・multicenter trial

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui. Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel. J Gastroenterol. 2025.05; 60 (5): 573-582. ( PubMed , DOI )2025
• Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res. 2024.07; 22 (3): 369-377. ( PubMed , DOI )2024
• Xiang Gao, Toshimitsu Fujii, Byong Duk Ye, Jen-Wei Chou, Ken Sugimoto, Qian Cao, Kristina Kligys, Kaoru Murakoshi, Dennis Teng, Yafei Zhang, Hiroshi Nakase. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. J Gastroenterol Hepatol. 2024.01; 39 (1): 55-65. ( PubMed , DOI )2024
• Marc Ferrante, Peter M Irving, Maria T Abreu, Jeffrey Axler, Xiang Gao, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Joana Torres, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Sofie Berg, Xiaomei Liao, Qing Zhou, Jasmina Kalabic, Brian Feagan, Remo Panaccione. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. J Crohns Colitis. 2024.03; 18 (3): 416-423. ( PubMed , DOI )2024

• Official profile